Journal article
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Abstract
BACKGROUND: Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis.
OBJECTIVE: To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks.
Authors
Blauvelt A; Reich K; Tsai T-F; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S
Journal
Journal of the American Academy of Dermatology, Vol. 76, No. 1, pp. 60–69.e9
Publisher
Elsevier
Publication Date
January 2017
DOI
10.1016/j.jaad.2016.08.008
ISSN
0190-9622